Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  0.50 0.16% 308.50 33,172 16:35:24
Bid Price Offer Price High Price Low Price Open Price
307.00 310.00 319.50 310.00 310.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 167.90 -67.95 -88.61 2,056
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:50 AT 11 310.00 GBX

Hutchison China Meditech (HCM) Latest News (3)

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
17/10/201915:33(Chi-Med)Hutchinson China Meditech Limited2,273
31/7/201807:25Hutchison Chi-Med (HCM) One to Watch 1
23/7/201810:55Hutchison Chi-Med (HCM) One to Watch on Monday 1
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech Limited is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 308p.
Hutchison China Meditech Limited has a 4 week average price of 260.50p and a 12 week average price of 260.50p.
The 1 year high share price is 567p while the 1 year low share price is currently 260.50p.
There are currently 666,577,450 shares in issue and the average daily traded volume is 118,602 shares. The market capitalisation of Hutchison China Meditech Limited is £2,056,391,433.25.
nerdofsteel: Next news due in no particular order 1. Inclusion of Elunate on the NRDL 2. Sumbission and acceptance of Surufatinib NDA 3. Savo / Taxotere® 2L gastric (VIKTORY)Ph. II Data 4. Fruqintinib 3L NSCLC (FALUCA)Ph. III Data* Items 1 and 2 are material in my view, although having said that when Fruquintinib was submitted and then approved there was no impact on the share price. Hopefully, as Surufatinib is wholly owned things will be different with this one!
sportii: Wondering if there have been any statements by the CEO or anyone from the BOD about sliding share price. There might be any legal binding to give any explanation, but, it could have helped the sentiments of investors still holding.
nerdofsteel: Sterlings appreciation against the USD has hit the share price yesterday/today I hold ADR's and London Ordinary shares so have a bit of a currency hedge The last Director Buys were by Dan Elder for $36.11 in March 2018 - which prompts the question why are Directors not buying now at these silly low prices? Current Headwinds 1. HHHL/CKH secondary listing overhang - probably finished 2. U.S. - China trade war 3. Hong Kong stability 4. Delay to HK IPO 5. Worldwide markets volatility 6. Trump China ADR de-listing threat (which has now been confirmed to be false) 7. China disliked by the U.S. and its Investment Community 8. GBP appreciation against sterling - likely to continue if Brexit is done & dusted
thornyone: Perhaps, Steeplejack, 'predictably' was the wrong word. I meant that the drop in HCM's share price since Jan 2018 was caused by various negative factors, an inevitable consequence of which was the drop. In other words, with hindsight the drop was predictable! It is just as predictable, therefore, that with good news, this drop will be erased. I notice a small uptick today ...
nerdofsteel: Now CKHH have reduce their holding below 50% let's hope we can get back to a proper valuation. Edison value the shares at £6.99 per share based on a DCF model, cash and IP. HCM’s recent share price underperformance provides an opportunity to revisit the investment case. We believe the long-term investment case is solid, with multiple near-term catalysts (regulatory filing and potential approval for surufatinib and savolitinib) as HCM successfully launches numerous assets to market (~2020/21 and beyond) in China and internationally. Its broad mid- to late-stage innovation platform (IP) will translate into diverse global revenue streams with a multitude of other compounds coming to the fore from HCM’s established and proven innovative R&D platform. Existing partnering deals for savolitinib and fruquintinib support the investment case as milestones and royalties on sales continue to bolster the P&L. HCM has global strategic aspirations, and it is only a matter of when rather than if its aspirations are met, in our view. HCM continues to invest in expanding its global innovation organisation; it now has >440 scientific personnel based in China and the US (Shanghai, Suzhou and New Jersey).
steeplejack: Indeed,an exciting test result would of course reverse the slide in the share price but I question whether the fall in the shares has been in anyway predictable.The erratic behaviour of the parent company is largely responsible for HCMs fall from grace.The decision to deconsolidate the subsidiary involved a pulled placing in Hong Kong.Without warning,the placing was hastily relocated to the Nasdaq to be executed by only one broker,Morgan Stanley,rather than the coterie of brokers (including Goldmans)originally planned to do the Hong Kong placing.The 24 dollar placing was badly handled and is primarily responsible for the price decline pre and post the issue.This is even more apparent in view of the recent successful placing professionally executed at $17.65.Benefit of hindsight is a erroneous commodity.If the fall in the share price was so very predictable,I feel sure that we would have seen a lot of shorting by those canny hedge funds.
thornyone: The HCM share price has been behaving predictably. From January 2018 the news has been solidly negative and this is reflected in the price dropping from $40 to $17 in waves. However, more than a reversal of these numbers is possible as soon as a globally exciting test result is received. Everything else, such as publicity about pipelines and listings is just a distracting sideshow.
waldron: 30/09/2019 3:08pm Dow Jones News Hutchison China Meditech (LSE:HCM) Intraday Stock Chart Today : Monday 30 September 2019 Click Here for more Hutchison China Meditech Charts. (Adds pricing of the offer, updates share price) By Adria Calatayud London-listed shares in Hutchison China MediTech Ltd. (HCM.LN) fell Monday after the company said shareholder CK Hutchison Holdings Ltd. (0001.HK) plans to sell a 1.3% stake. This would reduce CK Hutchison's stake in the company to 49.9% from 51.1%, allowing it to deconsolidate the investment from its financial statements, Hutchison China MediTech said. The offering price was set at $17.65 for each American depositary share, Hutchison China MediTech said. Each ADS represents five ordinary shares, the company said. The China-focused pharmaceutical company, which is listed in the U.K. and the U.S., said the Hong Kong-based conglomerate has no intention of selling additional shares in Hutchison China MediTech for the foreseeable future upon completion of the current offering. Hutchison China MediTech's London-listed shares at 1320 GMT were down 5% at 285 pence. Write to Adria Calatayud at (END) Dow Jones Newswires September 30, 2019 09:53 ET (13:53 GMT)
nerdofsteel: The 90 day lockup period has just ended this week It's also interesting to note that staff and senior Managers were given various Share Options in the last year at prices way above today's level, so I suspect they are very surprised we currently sit at March 2017 levels given the huge progress. Historically the Company has seen years of share price stagnation followed by very rapid price rises (2010, 2014, 2015, 2016 for example)
lauders: Not sure it is CH myself. It is a general lack of confidence after the badly handled HK listing lead-up and then postponment as well as some not so great news from the company. That did little to move the share price when some good news did arrive and now we are in limbo until some good news arrives and the market views HCM more favourably. Agree the spread is a disgrace post share adjustment! A narrower spread would help the investment case here.
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
Hutchison ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191017 17:51:49